Skip to main content

Generics

  • Lawmakers urge one-year transition period on Medicaid reimbursement implementation

    ARLINGTON, Va. — This week, 49 members of the U.S. House of Representatives urged Health and Human Services Secretary Kathleen Sebelius to adopt a one-year transition period for states to implement the July 2014 average manufacturer price-based federal upper limits. The National Association of Chain Drug Stores commended Reps. Mike Rogers, R-Mich., and Bruce Braley, D-Iowa, for leading the letter effort with their colleagues.

  • Teva's injunction on introduction of Mylan's generic Copaxone denied

    PITTSBURGH — Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. 

  • Suppliers counteract generic margin compression with targeted mergers, acquisitions

    By adding complementary specialty medication offerings to their generic drug businesses, manufacturers can add instant value and counteract the margin compression that is currently occurring as a result of high generic drug utilization.

  • ABC News to host live Twitter chat on pain management

    NEW YORK — ABC News will be hosting a live Twitter chat focusing on pain management on Tuesday, April 22, at 1 p.m., as part of the news agency's next ABC News National Tweet Chat. ABC plans to cover a range of topics related to pain management, including chronic pain and palliative care.

    To join in on the conversation, click here. 

  • Actavis to acquire five products from Akorn/Hi-Tech Pharmacal

    DUBLIN — Actavis on Friday announced that it has entered into agreements with Akorn and Hi-Tech Pharmacal to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

  • CDC: Evidence-based interventions reduces racial and ethnic health disparities

    ATLANTA — Evidence-based interventions at the local and national levels provide promising strategies for reducing racial and ethnic health disparities related to HIV infection rates, immunization coverage, motor vehicle injuries and deaths, and smoking, according to a new report by the CDC's Office of Minority Health and Health Equity released Thursday.

  • Study: Mondays may be 'mini New Year's' with regard to healthier behaviors

    SAN DIEGO — A new study in the American Journal of Preventive Medicine analyzing weekly patterns in health-related Google searches reveals a recurring pattern that could be leveraged to improve public health strategies.

  • Actavis, Forest Laboratories receive request for additional information from FTC

    DUBLIN  — Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest. 

    The effect of the second request is to extend the waiting period until 30 days after Actavis and Forest have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC.  

X
This ad will auto-close in 10 seconds